Literature DB >> 27108751

Quitline Activity in China.

Jijiang Wang1, Yi Nan, Yan Yang, Yuan Jiang.   

Abstract

In order to help smokers quit easier, China started to provide a quilting service in 2004. There are two models for the Chinese quitline service - the National Quitline Model, which provides only cessation service to smokers, and the 12320 Hotline Model, which integrates cessation counseling into the public health hotline service and is currently being adopted in public health hotlines in 28 provinces. A protocol of 4 counseling calls is used by 12320 Hotline. The three-month abstinence rate for clients is about 20%. The fact that most smokers who attempt to quit don't seek cessation help or quitline service is a major constraint for quitline services in China. Effective advocating campaigns should be implemented to propagate the quitline. Diverse protocols targeting different subpopulations also need to be developed to provide a better service to the public.

Mesh:

Year:  2016        PMID: 27108751     DOI: 10.7314/apjcp.2015.16.s2.7

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  3 in total

1.  Patients' self-reported receipt of brief smoking cessation interventions based on a decision support tool embedded in the healthcare information system of a large general hospital in China.

Authors:  Shuilian Chu; Lirong Liang; Hang Jing; Di Zhang; Zhaohui Tong
Journal:  Tob Induc Dis       Date:  2019-10-18       Impact factor: 2.600

2.  Smoking control in China: A need for comprehensive national legislation.

Authors:  Bo Xi; Costan G Magnussen
Journal:  PLoS Med       Date:  2022-08-25       Impact factor: 11.613

3.  Trends in smoking prevalence in urban and rural China, 2007 to 2018: Findings from 5 consecutive nationally representative cross-sectional surveys.

Authors:  Mei Zhang; Ling Yang; Limin Wang; Yong Jiang; Zhengjing Huang; Zhenping Zhao; Xiao Zhang; Yichong Li; Shiwei Liu; Chun Li; Linhong Wang; Jing Wu; Xinhua Li; Zhengming Chen; Maigeng Zhou
Journal:  PLoS Med       Date:  2022-08-25       Impact factor: 11.613

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.